Clinical trials: Hepatitis C Viral
HIV Infections, HCV
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
The goal of this pilot clinical trial is to learn if an intervention that trains Gancheros (people who provide injection services in exchange for drugs or money) to conduct risk-reduction outreach could help lower risk for human…
- Conditions
- HIV Infections, HCV, Overdose
- Trial name
- NCT06316739
- Testing
- Ganchero intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Cirrhosis
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2.
- Trial name
- NCT02113631
- Testing
- Telaprevir, Boceprevir, Peg-IFN
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Louis Stokes VA Medical Center
Chronic Hepatitis C
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
The primary objective of this program is to provide DCV for 24 weeks to be given in combination with SOF to subjects with chronic hepatitis C with decompensated cirrhosis or post-liver transplant subjects with chronic hepatitis C…
- Trial name
- NCT02161939
- Testing
- Daclatasvir (BMS-790052), Sofosbuvir
- Where
- 20 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants…
- Trial name
- NCT01353911
- Testing
- Grazoprevir, Boceprevir, Peg-interferon alfa-2b
- Volunteers
- 368 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Hepatitis C
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV.
- Trial name
- C_ASCENT (NCT02194998)
- Testing
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Hepatitis C
Australian Trial in Acute Hepatitis C Recall Study
A single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently…
- Trial name
- ATAHC Recall (NCT02000063)
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Kirby Institute
Hepatitis C
Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes
The current study has been designed to identify behavioral and physiological mechanisms through which positive social connectivity (PCS) and negative social processes (NSP) interact with psychosocial stress to promote resilience…
- Trial name
- NCT01625793
- Testing
- Interferon-alpha
- Where
- 2 sites in United States
- Sponsor
- University of Arizona
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
Clinical trials evaluating DAA have shown excellent rates of SVR and good safety profiles in patients with CHC infection. Real world data from TARGET, TRIO, IFI, DHCR, DALTON-C, as well as those cohorts from Japan, Taiwan and…
- Trial name
- C-DIAMOND (NCT04952207)
- Testing
- Direct-acting antiviral agents
- Where
- 11 sites in China
- Volunteers
- 300 people
- Sponsor
- Qing XIe
Hepatitis C, Chronic
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients…
- Trial name
- NCT01728324
- Testing
- Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment
- Where
- 109 sites in United States, Australia and 10 more
- Volunteers
- 496 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
Rosuvastatin for Hepatitis C
Objective: Determine if maximum doses of rosuvastatin are safe in patients infected with hepatitis C and if the so called pleiotropic effects of rosuvastatin cause a decrease in the HCV viral load. Primary study parameters: 1.
- Trial name
- NCT00371579
- Testing
- rosuvastatin
- Where
- Netherlands
- Sponsor
- UMC Utrecht
Hepatitis C, Chronic
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
This observational study will evaluate predictors of early on-treatment response and sustained virological response in patients with chronic hepatitis C receiving Pegasys (peginterferon alfa-2a) and ribavirin.
- Trial name
- NCT01392742
- Where
- 9 sites in Bulgaria
- Volunteers
- 443 people
- Sponsor
- Hoffmann-La Roche
Whole Cell Pertussis, Tetanus
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
This study will be conducted in two stages. In the diphtheria, tetanus, pertussis (DTP) booster phase, subjects will receive a booster dose of Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix (active control) at 15 to 18 or 24…
- Conditions
- Whole Cell Pertussis, Tetanus, Hepatitis B, Diphtheria
- Trial name
- NCT00228917
- Testing
- Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, Mencevax-ACWY
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
- Trial name
- NCT03020082
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 141 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Chronic Hepatitis C
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
The purpose of this study is to evaluate the quality of the RNA and the reproducibility of gene expression profiling from liver tissue samples obtained by fine needle aspiration.
- Trial name
- NCT00828269
- Testing
- Comparator: Fine needle aspiration biopsy
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was…
- Trial name
- NCT04443725
- Testing
- Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment
- Volunteers
- 100 people
- Sponsor
- Cairo University
Depression, HIV Infections
Trial of Citalopram for the Prevention of Depression
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV.
- Conditions
- Depression, HIV Infections, Hepatitis C
- Trial name
- PICCO (NCT00317746)
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Marina Klein
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences